Core Viewpoint - The announcement of the inclusion of the drug Pujihua (Pralsetinib capsules, 100mg) in China's National Medical Insurance Catalog has positively impacted the stock price of the company, leading to an increase of over 3% in early trading [1] Group 1: Stock Performance - The stock of the company, 基石药业-B, rose by over 3% in early trading and is currently up by 2.51%, priced at 5.71 HKD with a trading volume of 7.29 million HKD [1] Group 2: Drug Development and Commercialization - Pujihua has been developed by Blueprint Medicines, which was acquired by Sanofi in July 2025 [1] - The company holds exclusive development and commercialization rights for Pujihua in Greater China, including mainland China, Hong Kong, Macau, and Taiwan [1] - In November 2023, the company granted exclusive commercialization rights for Pujihua in mainland China to Shanghai Elios Pharmaceutical Technology Co., Ltd [1] Group 3: Regulatory Approval - The National Medical Insurance Catalog, which includes Pujihua, will officially take effect on January 1, 2026 [1]
基石药业-B早盘涨超3% 普拉替尼胶囊获纳入2025年国家医保目录